CytRx (CYTR) Initiates Phase 2 Trial with Bafetinib in B-cell Chronic Lymphocytic Leukemia
Tweet Send to a Friend
CytRx Corporation (NASDAQ: CYTR) announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
